Paraneoplastic hypoglycemia: An overview for optimal clinical guidance

Area of Science:

• Endocrinology and Oncology
• Metabolic Disorders

Background:

• Paraneoplastic hypoglycemia, or non-islet cell tumor hypoglycemia (NICTH), is a rare but serious complication of various malignancies.
• It is frequently associated with tumors that produce insulin-like growth factors (IGFs), primarily IGF-2 and its precursors.
• These IGFs disrupt glucose homeostasis, leading to excessive glucose utilization.

Purpose of the Study:

• To enhance the understanding of paraneoplastic hypoglycemia, focusing on its pathogenesis and diagnostic approaches.
• To provide guidance for optimal medical management of NICTH.
• To review current and emerging therapeutic strategies for IGF-2-mediated hypoglycemia.

Main Methods:

• Diagnosis involves documenting symptomatic hypoglycemia and excluding other causes.
• Key diagnostic tools include imaging studies and laboratory tests.
• Specific laboratory tests measure IGF-2 levels and the IGF-2:IGF-1 ratio.

Main Results:

• NICTH is characterized by hypoglycemia due to tumor-secreted IGFs.
• Diagnostic confirmation relies on clinical presentation, exclusion of other causes, and specific biomarker measurements.
• Treatment strategies are varied, addressing both the underlying tumor and the hypoglycemic state.

Conclusions:

• Effective management of NICTH requires a comprehensive approach integrating diagnosis and treatment.
• Surgical resection, pharmacological interventions (e.g., corticosteroids), and supportive care are current treatment mainstays.
• Emerging therapies targeting IGF-2, such as monoclonal antibodies and siRNA, offer promising future treatment avenues.